NLRP3 and type 2 diabetes mellitus: CY-09 directly binds to the ATP-binding region of NLRP3, inhibiting its ATP hydrolytic activity and blocking inflammasome assemble subsequently. Moreover, CY-09 showed good efficacy in mouse models of CAPS and type 2 diabetes mellitus.